Galmed Pharma (GLMD) Tops Q3 EPS by 19c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of $0.05, $0.19 better than the analyst estimate of ($0.14).

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• SpaceX: New Street Research sees 22% upside from proposed IPO price
• Victoria's Secret shareholders re-elect all nine board directors
• Oxford Industries (OXM) Tops Q1 EPS by 12c; Offers Outlook